Presentation is loading. Please wait.

Presentation is loading. Please wait.

Changes from baseline in (A) sputum cellularity and (B) endobronchial biopsy cellularity following 1 year of single maintenance and reliever therapy (SMART)

Similar presentations


Presentation on theme: "Changes from baseline in (A) sputum cellularity and (B) endobronchial biopsy cellularity following 1 year of single maintenance and reliever therapy (SMART)"— Presentation transcript:

1 Changes from baseline in (A) sputum cellularity and (B) endobronchial biopsy cellularity following 1 year of single maintenance and reliever therapy (SMART) (budesonide/formoterol 200/6 twice daily plus as needed) or fixed dose therapy (budesonide/formoterol 800/12 twice daily). Changes from baseline in (A) sputum cellularity and (B) endobronchial biopsy cellularity following 1 year of single maintenance and reliever therapy (SMART) (budesonide/formoterol 200/6 twice daily plus as needed) or fixed dose therapy (budesonide/formoterol 800/12 twice daily). Sputum and biopsy eosinophils decreased significantly with fixed dose combination therapy while with SMART there was a non-significant trend towards increased sputum eosinophils and a significant increase in biopsy eosinophils. p Values are between-treatment comparisons. Kenneth R Chapman et al. Thorax 2010;65: Copyright © BMJ Publishing Group Ltd & British Thoracic Society. All rights reserved.


Download ppt "Changes from baseline in (A) sputum cellularity and (B) endobronchial biopsy cellularity following 1 year of single maintenance and reliever therapy (SMART)"

Similar presentations


Ads by Google